BioTelemetry and CardioNet: The Diagnosis Behind the More Expensive Monitor

In the CardioNet 2015 settlement, BioTelemetry agreed to pay $6.4 million to resolve allegations of medically unnecessary cardiac monitoring that its subsidiary CardioNet billed to Medicare and other federal health programs. The government alleged that CardioNet billed for more expensive monitoring for patients with mild or moderate palpitations and supplied inaccurate diagnostic codes to justify it. The monitor collected the heart data. The alleged falsehood was in the medical need presented to the payer.

What the CardioNet 2015 Settlement Covered

The settlement concerned Mobile Cardiac Outpatient Telemetry and the diagnosis used to support payment for it. The Department of Justice announced the agreement on March 19, 2015, resolving allegations under the False Claims Act. BioTelemetry, headquartered in Malvern, Pennsylvania, was the parent company. CardioNet was the subsidiary whose billing the government investigated. The investigation grew out of an earlier qui tam case against LifeWatch.

The government alleged that CardioNet knew Medicare would not reimburse cardiac telemetry for patients who had experienced only mild or moderate heart palpitations because less expensive monitors could effectively collect the information about their condition.

How MCOT Differed From Lower-Cost Monitoring

MCOT continuously recorded the patient’s heart activity and used cellular technology to transmit the data to CardioNet’s diagnostic center. The patient wore the monitor while the system captured irregular rhythms and other cardiac events.

The Western District of Washington’s account explains the practical distinction. Cardiac telemetry could transmit continuously, while traditional, less expensive event monitors downloaded data periodically over a landline. The same account identifies event monitors and Holter monitors as less expensive alternatives that could effectively collect data about the patients whose claims were challenged.

The business records sit at different points along that chain. A clinic has the patient’s clinical assessment and monitoring order. A monitoring supplier has the device and transmission records. The payer has the claim and payment information. Putting those accounts together connects what the patient needed, what the company supplied and what it asked Medicare to pay.

The Diagnostic Code Made the Service Look Necessary

The national announcement describes the claim as carrying both the MCOT billing code and a diagnostic code that misrepresented the patient’s true condition.

Those codes served different purposes in the government’s account. The service code identified the monitoring being billed. The diagnostic code represented the medical condition supporting that claim.

For someone who handled these claims, the important information is the connection between records that other people saw separately. A clinical note may describe mild palpitations. A monitoring record may identify the service supplied. The submitted claim may describe a condition that appears to justify the more expensive monitoring. We examine how those descriptions came together and who was responsible for the choice.

Knowledge matters to this particular allegation because the government said CardioNet was aware of the reimbursement restriction. That makes the company’s understanding of the patient’s condition and the reason for selecting the diagnosis part of the story. An employee who understands how diagnoses reached the billing system can explain what the paid claim conceals.

LifeWatch and the Other CardioNet Settlements

The earlier LifeWatch allegations involved the same diagnostic mismatch: telemetry reimbursement for patients with only mild or moderate palpitations, supported by allegedly false diagnostic codes.

The CardioNet settlement announced in December 2022 concerned allegations that cardiac data for federal beneficiaries went to technicians in India for review, including technicians who lacked the required qualifications.

The LifeWatch settlement announced in December 2023 concerned enrollment choices that allegedly selected telemetry when physicians intended a less expensive service.

The distinction matters to someone inside a cardiac-monitoring business. The diagnosis attached to the claim, the service selected in the enrollment system and the location of the people reviewing the data are different decisions.

What an Insider Can See Behind the Claim

An insider’s value in a monitoring-billing case is knowing how the patient’s condition became the service and diagnosis submitted for payment. The CardioNet allegations connect those decisions. We work with the person who can explain where the descriptions diverged and how the business handled that divergence.

That is also where we focus with a potential whistleblower. Product knowledge explains the monitoring performed. Clinical knowledge explains the patient’s need. Billing knowledge explains the representation made to Medicare. A case about unnecessary telemetry depends on connecting that knowledge to the claims and the decisions that produced them.

You Know How the Diagnosis Reached the Bill

If you saw patient records, monitoring choices or diagnosis codes pushed toward a more expensive claim, talk to our whistleblower experts about the billing decisions you know. We build your strongest case with you, bring in healthcare fraud whistleblower lawyers who understand diagnostic testing and Medicare billing, and stay beside you as the case moves forward. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.